Testosteron schützte nicht vor Diabetes DOI

DMW - Deutsche Medizinische Wochenschrift, Journal Year: 2024, Volume and Issue: 149(20), P. 1186 - 1186

Published: Sept. 23, 2024

Testosterone Replacement Therapy and Risk of COVID-19 and Effect of COVID-19 on Testosterone's Treatment Effect DOI Creative Commons
Karol M. Pencina, A. Michael Lincoff, Eric A. Klein

et al.

Journal of the Endocrine Society, Journal Year: 2025, Volume and Issue: 9(3)

Published: Jan. 7, 2025

Abstract Context Whether circulating testosterone, dihydrotestosterone, and estradiol levels or testosterone replacement therapy (TRT) affects the risk of COVID-19 whether response to TRT remains unknown. Objective The study evaluated baseline are associated with developing treatment TRT. Methods Among 5204 men, aged 45 80 years, hypogonadism in TRAVERSE trial, 379 developed COVID-19. We compared on-treatment hormone levels, safety efficacy participants without diagnosis. Results Neither nor estradiol, dihydrotestosterone prior differed significantly between men Incidence was similar randomized placebo groups (3-year Kaplan-Meier incidence 8.0% 8.6% group, P = .823). Incidences COVID-19-related hospitalizations (38.5% vs 32.8%, .222) deaths (12.8% 8.9%, .247) were groups. Changes hypogonadal symptoms, libido, energy, hemoglobin/hematocrit attenuated testosterone-treated who major adverse cardiovascular events, venous thromboembolism, acute kidney injury those diagnosis without. Conclusion In disease (CVD) increased CVD, pre-COVID-19 did not. not affect

Language: Английский

Citations

2

Male hypogonadism: pathogenesis, diagnosis, and management DOI
Nipun Lakshitha de Silva, Nikoleta Papanikolaou, Mathis Grossmann

et al.

The Lancet Diabetes & Endocrinology, Journal Year: 2024, Volume and Issue: 12(10), P. 761 - 774

Published: Aug. 16, 2024

Language: Английский

Citations

7

Testosterone therapy in older men: clinical implications of recent landmark trials DOI Creative Commons
Mathis Grossmann,

Bradley D. Anawalt,

Bu B. Yeap

et al.

European Journal of Endocrinology, Journal Year: 2024, Volume and Issue: 191(1), P. R22 - R31

Published: June 25, 2024

Testosterone therapy for men with hypogonadism due to identifiable hypothalamic-pituitary-testicular (HPT) pathology is uncontroversial. However, the risks and benefits of testosterone clinical features in absence HPT axis have been uncertain. Recent landmark placebo-controlled trials assessed (≤3 years) middle-aged older symptoms possible signs or end-organ androgen deficiency, low low-normal serum concentrations, but no pathology: (1) had modest-but clinically significant-benefits on average self-reported energy mood, sexual function, satisfaction; (2) conjunction a lifestyle programme, reversed reduced incident type 2 diabetes mellitus (T2D) at high risk newly diagnosed T2D; (3) modestly improved objectively muscle strength timed walking distance; (4) increased bone density strength, did not reduce falls typical osteoporotic fractures surprisingly typically attributable trauma; (5) significantly increase myocardial infarction, stroke, prostate cancer. These help inform decision-making about men.

Language: Английский

Citations

4

Male Hypogonadism: The Korean Society of Men's Health and Aging Position Statement DOI Creative Commons
Sun Tae Ahn, Young‐Sang Kim, Sung Hoon Yu

et al.

The World Journal of Men s Health, Journal Year: 2025, Volume and Issue: 43

Published: Jan. 1, 2025

The Korean Society of Men's Health and Aging (KSMHA) acknowledges the necessity for an updated statement on testosterone therapy driven by evolving clinical practices new research findings. primary purpose this position is to provide a tailored, evidence-based framework that aligns with international best while addressing unique needs population. Additionally, addresses growing recognition both organic functional hypogonadism, particularly given rising rates obesity metabolic syndrome, which affect levels overall health. key areas, including laboratory diagnosis male focus appropriate cut-off values in men, provides guidance assessing treatment outcomes. In statement, we present objective based recent studies have carefully evaluated its effectiveness safety. By providing tailored management KSMHA aims enhance patient care align global standards.

Language: Английский

Citations

0

Reproductive and nonreproductive actions of testosterone DOI
Thiago Gagliano‐Jucá,

Arpit Jain,

Ravi Jasuja

et al.

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0

Letter to the Editor on “Association of total testosterone levels with cardiometabolic diseases in men with erectile dysfunction” DOI Creative Commons
Scott Selinger,

Gregory R. Thoreson

Sexual Medicine, Journal Year: 2025, Volume and Issue: 13(2)

Published: April 1, 2025

Language: Английский

Citations

0

Testosterone Therapy in Older Men: Present and Future Considerations DOI Creative Commons
Bu B. Yeap, Cammie Tran,

Catherine M. Douglass

et al.

Drugs & Aging, Journal Year: 2025, Volume and Issue: unknown

Published: April 27, 2025

Testosterone is the classical male anabolic hormone, involved in sexual development, virilisation and regulation of body composition adult men. Organic disease involving hypothalamus, pituitary or testes may interfere with endogenous testosterone production. In such men, treatment effectively ameliorates symptoms signs androgen deficiency. However, non-gonadal factors including age, mass index medical comorbidities influence circulating testosterone, older men have on average lower concentrations compared younger these would be a pharmacological intervention requiring stringent justification via high-quality evidence from randomised controlled trials (RCTs). Recent RCTs show benefits to improve function, anaemia bone mineral density prevent revert type 2 diabetes mellitus at high risk. Results large cardiovascular safety trial risk provide important reassurance as prostate treatment. Key questions remain whether testosterone's other effects can used safely counter reductions lean associated incretin-based weight loss medications obesity, it might disabilities frailty, osteoporotic fractures dementia generally. This last question could answered by new RCT, targeting 65-80 years age bracket, which necessarily extended duration. A composite endpoint integrates potential risks, disability-free survival.

Language: Английский

Citations

0

Hormonal regulation of carbohydrate metabolism in men with type 2 diabetes mellitus and hypogonadism DOI
Д. В. Скуридина,

A. N. Levitskaya

FOCUS Endocrinology, Journal Year: 2025, Volume and Issue: 6(1), P. 13 - 19

Published: May 16, 2025

The aim . Study of the features hormonal regulation carbohydrate metabolism in men with type 2 diabetes mellitus (T2DM) and hypogonadism by assessing beta alpha cell function, as well degree insulin resistance (IR). Material methods study included 271 T2DM. Group 1 consisted patients T2DM confirmed (n=126), group without (n=145). Body mass index, waist circumference, hip fasting plasma glucose, glycated hemoglobin, triglycerides (TG), insulin, C-peptide, glucagon, HOMA-IR, HOMA-β, TYG indices were evaluated. Results. In hypogonadism, IR tended to be higher according HOMA-IR index (Δ0.41, p=0.07), significantly (Δ0.14, p <0.05). Also, 1, TG level was (Δ0.33, <0.05), values C-peptide (Δ0.4 ng/ml, (Δ3.3 mIU/ml, <0.05) HOMA-β (Δ15.7 or 84%, <0.001). A moderate negative correlation observed between total testosterone (r=-0.364, median glucagon lower – 46 versus 98.6 pg/ml (p All from who had their basal levels assessed less than 150 pg/ml. Conclusion : presence functional is associated a more pronounced IR. significant difference level, inverse confirm that can considered an independent cardiovascular risk factor. characterized absence hyperglucagonemia.

Language: Английский

Citations

0

Mechanisms in Endocrinology: Hypogonadism and metabolic health in men - novel insights into pathophysiology DOI Creative Commons
Clare Miller,

Lauren Madden-Doyle,

Channa Jayasena

et al.

European Journal of Endocrinology, Journal Year: 2024, Volume and Issue: 191(6), P. R1 - R17

Published: Sept. 30, 2024

Abstract Hypogonadism in men is associated with an adverse metabolic phenotype and increased mortality. Reciprocally, obesity insulin resistance can suppress the hypothalamic–pituitary–gonadal axis absence of structural organic disease, further perpetuating a cycle dysfunction low testosterone. The mechanisms underpinning this bidirectional association are complex as hypogonadism heterogenous syndrome, perturbations glucose lipid metabolism even presence normal testicular function. However, distinct molecular defects specific to testosterone deficiency have been identified pathways relating target depots such adipose tissue skeletal muscle. This review discusses etiology prevalence disease male hypogonadism, focus on both novel potential approaches enhance our understanding.

Language: Английский

Citations

3

Testosterone Replacement Therapy and Diabetes in Men With Hypogonadism DOI
Lona Mody,

Kenneth E. Covinsky

JAMA Internal Medicine, Journal Year: 2024, Volume and Issue: 184(4), P. 362 - 362

Published: Feb. 5, 2024

Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals Network Open Cardiology Dermatology Health Forum Neurology Oncology Ophthalmology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy Accessibility Statement 2024 American Medical Association. All Rights Reserved Search Archive Input Term Sign In Individual inCreate an Account Access through institution Purchase Options: Buy this article Rent Subscribe the journal

Language: Английский

Citations

1